《美股業績》吉利德季度虧轉盈 瑞德西韋銷售勝預期
生產新冠藥物瑞德西韋的美國藥廠吉利德科學(Gilead Sciences)(GILD.US)公佈第二季度業績。季度純利15.22億美元,對上年度虧損33.39億美元。每股季度攤薄純利1.21美元,經調整後爲1.87美元,高於市場預測的1.75美元。季度派息每股71美仙。
季度收入62.17億美元,按年升20.9%,高於市場預期的60.7億美元。其中愛滋病藥物銷售按年減少2%至39.38億美元。瑞德西韋銷售額爲8.29億美元,高於市場預期的6.75億美元。
公司預期全年銷售介乎244億至250億美元,每股經調整純利介乎6.9至7.25美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.